Syphilis
"A Randomized Trial of Enhanced Therapy for Early Syphilis in Patients with and Without Human Immunodeficiency Virus Infection."
Published in AIDS Weekly, September 8th, 1997
According to the authors' abstract of an article published in New England Journal of Medicine, "Background: Reports of neurosyphilis and invasion of cerebrospinal fluid by Treponema pallidum in patients with human immunodeficiency virus (HIV) infection have led to doubts about the adequacy of the recommended penicillin G benzathine therapy for early syphilis. Methods: In a multicenter, randomized, double-blind trial, we assessed two treatments for early syphilis: 2.4 million units of penicillin G benzathine and that therapy enhanced with a 10-day course of amoxicillin and probenecid. The serologic and clinical responses of patients with and without HIV infection...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (1997-09-08)
More Articles from AIDS Weekly
- AIDS Vaccines
AIDS Docs Sign Up For Live Vaccine Trial - AIDS Therapies
Escape From Anti-HIV MAbs Costly For Virus - AIDS Therapies
Passive Immunization Yields High Levels of Anti-HIV Antibody - AIDS Therapies
Zerit Approved For First-Line Treatment of HIV in Europe - At-Risk Populations (Behavior)
Risky Sex, STDs, Condom and Drug Use Affect Risk for Straight Couples - Caregiving
AIDS Hospice Closes for Lack of Patients - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
